Management of Relapsed/Refractory Multiple Myeloma with Bispecifics: MonumenTAL-2, MajesTEC-1, and MagnetisMM-3 trials
Panelists discuss recent updates in the management of relapsed/refractory multiple myeloma, focusing on key studies such as MonumenTAL-2 for talquetamab, long-term follow-up data from the phase 1/2 MajesTEC-1 for teclistamab, and findings from MagnetisMM-3 regarding elranatamab.
Video content above is prompted by the following:
Comment on the recent updates surrounding the management of R/R MM with bispecifics and bispecific combination therapies:
- MonumenTAL-2 for talquetamab (Schinke CD et al. ASCO 2023 Abstract 8036)
- Long-term follow-up from the phase 1/2 MajesTEC-1 for teclistamab (Garfall et al. ASCO 2024 Abstract 7540)
- MagnetisMM-3for elranatamab in R/R MM (Lesokhin A, Nature 2023)
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
